Key Highlights

  • Orthocell reported FY2026 Revenue of AUD 13.2 million, up 44% year on year.
  • US hospitals purchasing Remplir increased 27% to 70 during the June quarter.
  • Surgeon adoption climbed 55% to 76 users as the distributor network expanded.
  • Orthocell reported AUD 44.1 million in available funds to support US commercialisation.

Orthocell (ASX: OCC) is a Western Australian regenerative medicine company that has moved from a long clinical development story into an early commercial one, and that transition is what makes it one of the more interesting healthcare names on the ASX right now. Its lead product, Remplir, is a collagen-based nerve-repair wrap used in surgery, and after securing US clearance the company is now in the critical phase of proving it can turn regulatory success into sustained sales in the world's largest medical-device market.

A record year built on US momentum

Orthocell's FY2026 result, reported on 12 July 2026, showed total revenue of $13.2 million, up 44% year on year, with the June quarter contributing $3.8 million. The most watched figure was US Remplir revenue, which reached about $330,000 in the June quarter, a 10% increase on the prior quarter. On its own that number is small, but it is the trajectory and the underlying account growth that matter at this stage of a commercial ramp.

The operational metrics behind that revenue are the more telling part of the story. The number of US hospitals purchasing Remplir rose 27% to 70, surgeon adoption climbed 55% to 76 users, and the distributor network now reaches roughly half of the US population. The company also reported 44 value-analysis-committee approvals, the internal hospital sign-offs required before a device can be used, with 151 hospitals now having access. During the June quarter it sold 119 Remplir units.

Expanding the addressable market

Two developments have widened the runway. Orthocell secured approval to Supply Remplir into the US Department of Defence and Veterans Affairs networks, which between them encompass a large number of facilities, opening a channel that many small device companies never reach. Separately, its Striate+ dental membrane product gained regulatory approval in Colombia and Ecuador, with commercial launches expected across those markets and Brazil in the second half of 2026, adding a second, smaller commercial leg.

Crucially, the company said it is funded for this expansion. It reported about $44.1 million in available funds, comprising cash and securities, and stated this was sufficient to support US commercialisation without requiring additional funding. For a company at this stage, a self-funded runway removes one of the biggest overhangs that typically weighs on early-commercial MedTech stocks.

Why it matters and what could go wrong

The bull case is that Orthocell has a cleared product, a growing base of hospitals and surgeons, a broadening distribution footprint and the Balance Sheet to see the rollout through. If US account growth continues to compound, the revenue base could scale meaningfully from a low starting point, and the addressable nerve-repair market is large.

The risks are those of any commercialisation story. Current US Remplir revenue remains modest, and the market is effectively pricing future adoption rather than today's sales, which raises expectations. Building surgeon habits and winning hospital committee approvals takes time, competition in surgical repair is entrenched, and any slowdown in the quarter-on-quarter progression would quickly test sentiment.

For investors, Orthocell sits at the point where a healthcare story either accelerates or stalls. The catalysts to watch are simple: continued growth in US hospital accounts, surgeon adoption and quarterly Remplir sales, plus early traction from the Department of Defence channel and the Striate+ launches. On the evidence of FY2026, the execution is heading the right way, which is what keeps this one firmly on the healthcare watchlist.